MediWound (MDWD) Projected to Post Earnings on Thursday

MediWound (NASDAQ:MDWD) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect MediWound to post earnings of ($0.76) per share and revenue of $2.5890 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

MediWound (NASDAQ:MDWD) last released its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Down 0.8%

Shares of MDWD opened at $14.19 on Thursday. The stock’s fifty day simple moving average is $14.38 and its 200-day simple moving average is $16.11. The firm has a market capitalization of $182.34 million, a PE ratio of -6.28 and a beta of 0.15. MediWound has a 12-month low of $13.54 and a 12-month high of $20.30.

Insiders Place Their Bets

In related news, Director David Morton Fox bought 3,537 shares of MediWound stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the acquisition, the director owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP bought a new position in MediWound during the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets increased its stake in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares in the last quarter. Russell Investments Group Ltd. increased its stake in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the fourth quarter worth $109,000. 46.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $34.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.